[Drug discovery in the fields of urology: tamsulosin and solifenacin].
Miyata
Keiji
K
D000317:Adrenergic alpha-Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001682:Biological Availability; D018680:Cholinergic Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D015195:Drug Design; D006801:Humans; D008297:Male; D011812:Quinuclidines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D043587:Receptor, Muscarinic M3 / Q000037:antagonists & inhibitors*; D000069464:Solifenacin Succinate; D013449:Sulfonamides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000077409:Tamsulosin; D044005:Tetrahydroisoquinolines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001743:Urinary Bladder / Q000187:drug effects; D014555:Urination Disorders / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D018680:Cholinergic Antagonists; D003692:Delayed-Action Preparations; D011812:Quinuclidines; D043587:Receptor, Muscarinic M3; D013449:Sulfonamides; D044005:Tetrahydroisoquinolines; D000077409:Tamsulosin; D000069464:Solifenacin Succinate